NODYSIS PH. - search results

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

farmalinx launcher ph indicator and buffering adjuvant

farmalinx pty ltd - nonyl phenol ethoxylate; phosphoric acid derivatives - soluble concentrate - nonyl phenol ethoxylate emulsifiers & surfactants-noni active 266.2 g/l; phosphoric acid derivatives mineral-phophorus-acid active 375.1 g/l - adjuvant - wetting agent | spreader | surfactant - spreader spray (refer to directions)

New Zealand - English - Medsafe (Medicines Safety Authority)

creon 10,000

viatris limited - pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.); pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. - modified release capsule - 150 mg - active: pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide black iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. excipient: cetyl alcohol dimeticone ferrosoferric oxide gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

creon 25,000

viatris limited - pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.); pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u; pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u - modified release capsule - 300 mg - active: pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

creon micro

viatris limited - pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) - modified release granules - 60.12 mg - active: pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) excipient: cetyl alcohol dimeticone hypromellose phthalate macrogol 4000 triethyl citrate - for treatment of conditions associated with pancreatic exocrine insufficiency, such as: cystic fibrosis, chronic pancreatitis, post-pancreatectomy, post-gastrointestinal bypass surgery, e.g. billroth ii, gastroenterostomy; ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

concentrated antigens of dichelobacter nodosus, serotype a, b1, b2, c, d, e, f, g, h and i

intervet australia pty limited - dichelobacter nodosus serotypes a,b,c,d,e,f,g,h,i - unknown - dichelobacter nodosus serotypes a,b,c,d,e,f,g,h,i vaccine-antigen/antibody active 0.0 - active constituent